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Objective. To assess the frequency of venous thromboembolism (VTE) events in the Rituximab in Antineutrophil 
Cytoplasmic Antibody (ANCA)–Associated Vasculitis (RAVE) trial and identify novel potential risk factors.
Methods. VTE events in 197 patients enrolled in the RAVE trial were analyzed. Baseline demographic and clinical 
characteristics were recorded, and univariate and multivariate analyses were performed to identify factors associated 
with VTE in ANCA- associated vasculitis (AAV).
Results. VTE occurred in 16 patients (8.1%) with an overall average time to event of 1.5 months (range 1.0–2.75). 
In  univariate analyses with calculation of hazard ratios (HRs) and 95% confidence intervals (95% CIs), heart involve-
ment (HR 17.408 [95% CI 2.247–134.842]; P = 0.006), positive proteinase 3 (PR3)–ANCA (HR 7.731 [95% CI 1.021–
58.545]; P = 0.048), pulmonary hemorrhage (HR 3.889 [95% CI 1.448–10.448]; P = 0.008), and the presence of red 
blood cell casts (HR 15.617 [95% CI 3.491–69.854]; P < 0.001) were associated with the onset of VTE. In multivariate 
models adjusted for age and sex, the significant associations between VTE events and heart involvement (HR 21.836 
[95% CI 2.566–185.805]; P = 0.005), PR3- ANCA (HR 9.12 [95% CI 1.158–71.839]; P = 0.036), pulmonary hemorrhage 
(HR 3.91 [95% CI 1.453–10.522]; P = 0.007), and urinary red blood cell casts (HR 16.455 [95% CI 3.607–75.075]; 
P < 0.001) remained.
Conclusion. Patients diagnosed as having AAV with pulmonary hemorrhage, positive PR3- ANCA, heart involve-
ment, and the presence of red blood cell casts are at an increased risk to develop VTE. Further studies are needed 
to confirm and expand these findings and to explore the mechanisms of hypercoagulability in these patients with the 
aim of informing potential targets for therapeutic intervention.
INTRODUCTION
The therapeutic methods available to treat antineutrophil cyto-
plasmic antibody (ANCA)–associated vasculitides (AAVs) expanded 
with the approval of rituximab (RTX) as an alternative therapy to 
cyclophosphamide (CYC) as the induction treatment for granu-
lomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) 
(1,2). As treatment approaches and patient survival have improved 
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over the past decades, longer- term outcome and complications 
attributable to either the disease or immunosuppressive therapy 
have moved into the research focus. Consequently, recent reports 
have highlighted an increased frequency of venous thromboembo-
lism (VTE) events in patients with AAV. Analysis of a randomized 
controlled trial that included patients with GPA enrolled in the 
Wegener’s Granulomatosis Etanercept Trial (WGET) demonstrated 
an incidence of VTE of 7.0 per 100 person- years (3). An increased 
likelihood of VTE was reported in a population- based incident 
AAV cohort, which was driven by a significantly increased risk of 
developing deep venous thrombosis (DVT) (4). Analysis of a large 
cohort of patients with eosinophilic granulomatosis with polyangiitis 
(EGPA), GPA, and MPA demonstrated occurrence of VTE in 8.2%, 
8.0%, and 7.8% of patients, respectively (5). More recently, analysis 
of data derived from several trials conducted by the European Vas-
culitis Society showed the occurrence of VTE in 41 (9.8%) of 417 
patients with GPA or MPA (6). While VTE is now acknowledged as a 
commonly occurring complication of AAV, its pathogenesis remains 
ill- defined. Several factors have been considered to play a role in 
VTE pathogenesis, including the presence of antiplasminogen 
antibodies (7) and excess thrombin generation facilitated by tissue 
 factor, microparticles, and neutrophil extracellular traps (8).
The aim of the current study was to further explore the rela-
tionship between VTE and AAV through analysis of data from the 
Rituximab in ANCA- Associated Vasculitis (RAVE) trial (1). This trial 
allowed for prospective follow- up of patients with GPA and MPA 
and presented the first opportunity to study the impact of 2 differ-
ent induction treatment strategies, namely RTX and CYC, on the 
occurrence of VTE events.
PATIENTS AND METHODS
Study design and treatment regimens. The RAVE study 
was a double- blind, placebo- controlled trial in which 197 patients 
were randomized to receive either RTX (375 mg/m2 weekly for 4 
weeks; n = 99) or CYC (2 mg/kg body weight for 3–6 months) fol-
lowed by maintenance treatment with azathioprine (2 mg/kg body 
weight, maximum dosage 150 mg/day; n = 98). Glucocorticoids 
were tapered and withdrawn within 5.5 months in both groups. 
Detailed trial design and the respective results for short- and the 
long- term follow- up have been previously described (1,9).
Definitions of outcome variables. Patients were clas-
sified according to their AAV diagnosis (GPA or MPA) based on 
the 1994 Chapel Hill Consensus Conference Nomenclature for 
Vasculitis (10). Patients were further classified according to either 
proteinase 3 (PR3)–ANCA or myeloperoxidase (MPO)–ANCA. 
Information related to patient demographic characteristics, 
newly diagnosed/relapsing disease, specific organ involvement, 
treatment, and outcome was collected. Vasculitis activity was 
assessed using the Birmingham Vasculitis Activity Score for 
Wegener’s Granulomatosis (BVAS/WG) (11), and the Vasculitis 
Damage Index was used to grade the respective damage (12). 
The occurrence of either DVT, pulmonary embolism (PE), or both 
was considered a VTE event.
Statistical analysis. For baseline characteristics, the 
number and percent of patients, mean ± SD, or median with 
inter quartile range was used for analysis, as appropriate. Charac-
teristics between patients with and those without VTE were com-
pared by Student’s t- test or Mann- Whitney test for continuous 
data and chi- square test or Fisher’s exact test for categorical data. 
Spearman’s correlation coefficient was used to report the relation-
ship between VTE and named factors or states.
Kaplan- Meier curves were plotted for the occurrence of first 
VTE events and significant variables. Survival curves were com-
pared by log rank test. Univariate Cox regression models were 
used to assess the effect of factors and states in patients with and 
those without VTE. For every significant parameter in univariate 
analyses, a multivariate Cox regression model with adjustment for 
age and sex was applied. Findings of the univariate and multivar-
iate analyses were assessed using hazard ratios (HRs) and 95% 
confidence intervals (95% CIs). P values less than 0.05 were con-
sidered significant.
RESULTS
Patient characteristics stratified by VTE. Of the 197 
patients enrolled in the RAVE trial, 42 (21.3%) received antico-
agulation therapy as either thromboprophylaxis or due to an ear-
lier medical history necessitating anticoagulation treatment (such 
as atrial fibrillation). VTE events were recorded in 16 patients. Of 
these, 11 patients had DVT, 4 had PE, and 1 had concomitant 
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DVT and PE. Overall, the average time from baseline to VTE was 
1.5 months (range 1.0–2.75) (see Supplementary Table 1, availa-
ble on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.41017/ abstract).
A higher BVAS/WG at baseline was recorded for patients with 
VTE versus those without VTE (HR 10 [95% CI 9–11.75] versus 8 
[95% CI 6–10]; P = 0.017). We observed a higher frequency of 
VTE events among patients with PR3- ANCA (15 events among 
133 patients) than among those with MPO- ANCA (1 event among 
64 patients) (P = 0.016). Moreover, pulmonary hemorrhage and 
heart involvement were more frequent in the VTE group (P = 0.004 
and P = 0.001, respectively). Of the 16 VTE events, 7 occurred in 
RTX- treated patients and 9 in CYC- treated patients (P = 0.558). 
In contrast, sinusitis was less frequently observed in patients who 
experienced a VTE event than those who did not (31.3% versus 
56.9%; P = 0.048) (see Supplementary Table 2, http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41017/ abstract). A positive 
correlation was observed between VTE and heart involvement 
(r = 0.24, P < 0.01), pulmonary hemorrhage (r = 0.21, P < 0.01), 
positive PR3- ANCA (r = 0.17, P < 0.05), BVAS/WG (r = 0.17,  P < 
0.05), and the presence of red blood cell (RBC) casts (r = 0.373, 
P < 0.001). There was a negative association between VTE and 
eye involvement (r = –0.16, P < 0.05) and sinusitis (r = –0.14, 
P < 0.05) (see Supplementary Table 3, available on the Arthri-
tis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41017/ abstract). Kaplan- Meier curves for pulmo-
nary hemorrhage,  positive PR3- ANCA, and RBCs are shown in 
Figure 1.
Predictors of VTE. Univariate analyses were performed 
to identify variables associated with VTE. Among clinical fac-
tors found to have significant values, we demonstrated heart 
involvement (HR 17.408 [95% CI 2.247–134.842]; P = 0.006), 
PR3 positivity (HR 7.731 [95% CI 1.021–58.545]; P = 0.048), 
Figure 1. Kaplan-Meier analysis of the association between venous thromboembolism (VTE) and pulmonary hemorrhage, proteinase 
3 (PR3) positivity, and the presence of red blood cell (RBC) casts. A, Event-free survival of patients with and patients without pulmonary 
hemorrhage (P < 0.003). B, Time to VTE event according to the specific antigen (PR3 versus myeloperoxidase [MPO]) (P < 0.018). C, Time 
to VTE event in patients with RBC casts compared to those without significant RBC casts (P < 0.001). All analyses were calculated from 
trial entry.
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pulmonary hemorrhage (HR 3.889 [95% CI 1.448–10.448]; 
P = 0.008), and presence of RBCs (HR 15.617 [95% 3.491–
69.854]; P < 0.001) to be positively associated with VTE events. 
The  frequency of VTE was similar in both treatment groups (RTX 
 versus CYC) (HR 0.747 [95% 0.278–2.006]; P = 0.563), and 
there was no difference between newly diagnosed patients and 
patients with relapsing disease (HR 1.067 [95% CI 0.400–2.844]; 
P = 0.896) (Table 1). Multivariate models adjusted for age and 
sex were used to confirm the associations identified by univariate 
analyses. After adjustment for demographic variables, the asso-
Table 1. Univariate Cox regression results indicating the association between clinical variables and VTE events in 197 
patients with antineutrophil cytoplasmic antibody–associated vasculitis*
Variable
Median value or  
% of patients HR (95% CI) P
Demographics and baseline clinical 
characteristics
Age, median years 52 1.005 (0.973–1.039) 0.745
Body mass index, median kg/m2 27.6 1.042 (0.974–1.116) 0.229
Creatinine, median mg/dl 1.2 1.209 (0.524–2.167) 0.524
BVAS/WG score, median 8 1.121 (0.994–1.264) 0.063
C- reactive protein, median mg/dl 3.03 1.051 (0.960–1.150) 0.282
GPA vs. MPA, % 74.7 1.941 (0.529–7.125) 0.317
Newly diagnosed disease vs. relapsing 
disease, %
48.7 1.067 (0.400–2.844) 0.896
PR3 vs. MPO positivity, % 66.5 7.731 (1.021–58.545) 0.048
Proteinuria (dipstick), % 72.1 0.675 (0.358–1.274) 0.226
Serum albumin, median gm/dl 3.75 1.353 (0.549–3.333) 0.511
Male sex, % 50.7 1.319 (0.491–3.542) 0.583
Disease manifestations, %
Arthralgia 56.3 0.988 (0.368–2.653) 0.981
Eye involvement 23.4 0.032 (0.000–4.322) 0.169
Heart involvement 0.5 17.408 (2.247–134.842) 0.006
Peripheral nervous system involvement 19.3 0.966 (0.275–3.391) 0.957
Pulmonary hemorrhage 25.9 3.889 (1.448–10.448) 0.008
Red blood cell casts 23.8† 15.617 (3.491–69.854) <0.001
Renal involvement‡ 28.5 2.238 (0.638–7.855) 0.208
Sinusitis 54.8 0.355 (0.123–1.023) 0.055
Skin involvement 17.3 1.634 (0.527–5.070) 0.395
VDI at baseline, median 1.18 0.793 (0.528–1.192) 0.265
Treatment modalities, %
Antihypertensive agents 100 1.189 (0.788–1.794) 0.410
Diuretic use (single agent) 24.9 1.389 (0.482–4.000) 0.542
Methylprednisolone bolus 64.5 0.415 (0.154–1.114) 0.081
Rituximab vs. cyclophosphamide 50.8 0.747 (0.278–2.006) 0.563
Sequential nephron blockade (loop and 
thiazide diuretics)
2.5 1.001 (0.623–1.609) 0.995
Cumulative steroid dose (6 months), 
median gm
3.99 0.673 (0.426–1.064) 0.090
Follow- up variables, %
Infection 82.2 1.526 (0.347–6.716) 0.526
Malignancy 3.6 0.047 (0.000–4,691.49) 0.603
Relapse 40.1 1.437 (0.539–3.831) 0.511
VDI change (>1)§ 0.998 (0.817–1.219) 0.984
* VTE = venous thromboembolism; HR = hazard ratio; 95% CI = 95% confidence interval; BVAS/WG = Birmingham Vascu-
litis Activity Score for Wegener’s Granulomatosis; GPA = granulomatosis with polyangiitis; MPA = microscopic polyangiitis; 
PR3 = proteinase 3; MPO = myeloperoxidase; VDI = Vasculitis Damage Index. 
† Data were available for 165 patients. 
‡ Renal involvement was defined as the presence of significant hematuria, red blood cell casts, or reduced creatinine 
clearance (attributable to active vasculitis). 
§ Excluding pulmonary infarction and complicated venous thrombosis. 
Table  2. Clinical associations with venous thromboembolism 
events in antineutrophil cytoplasmic antibody–associated vasculitis, 
determined by multivariate analysis of variables that had significant 
associations in the univariate analysis*
Variable Hazard ratio (95% CI) P
Heart involvement 21.836 (2.566–185.805) 0.005
Pulmonary hemorrhage 3.910 (1.453–10.522) 0.007
Proteinase 3 positivity 9.120 (1.158–71.839) 0.036
Red blood cell casts 16.455 (3.607–75.075) <0.001
* Multivariate Cox regression models were adjusted for age and sex. 
95% CI = 95% confidence interval. 
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ciations between VTE and the presence of heart  involvement 
(HR 21.836 [95% CI 2.566–185.805]; P = 0.005), pulmonary 
hemorrhage (HR 3.91 [95% CI 1.453–10.522]; P = 0.007), 
PR3 positivity (HR 9.12 [95% CI 1.158–71.839]; P = 0.036), 
and presence of RBCs (HR 16.455 [95% CI 3.607–75.075]; 
P < 0.001) remained significant (Table 2).
DISCUSSION
A hallmark of some systemic autoimmune diseases is their 
association with thrombosis (13). Consistent with this, several 
studies have shown that patients with AAV are at increased risk 
of developing thrombosis (3,5,13). When analyzing data from the 
RAVE trial, we observed VTE events in 8.1% of patients enrolled in 
the study. A majority of events (12 of 16) was recorded within the 
first 2 months of enrollment, highlighting the role of inflammation 
and presumably active disease in the onset of VTE. These findings 
align with previous results from the WGET trial, which indicated an 
increased risk of VTE in this patient population and a median time 
to event onset of 2.1 months (3). Moreover, we identified a trend 
toward an association between VTE and disease activity. A recent 
analysis of 417 patients from several randomized trials demon-
strated an association between higher disease activity and VTE 
events (6), reinforcing the role of active vasculitis in predisposing 
individuals to thrombosis.
Several mechanisms may contribute to the procoagulable 
state in AAV. Antiplasminogen antibody titers have been shown 
to be higher in patients with PR3- positive vasculitis compared to 
patients with either MPO- positive vasculitis or idiopathic thrombo-
sis, and these antibodies were detected in 5 of 9 vasculitis patients 
with thrombosis and PR3- ANCA positivity compared to none of 4 
patients with thrombosis and MPO- ANCA positivity (7). Antiplas-
minogen antibodies also reacted with a highly restricted motif on 
plasminogen (7), indicating their potential to impair fibrinolysis, which 
may explain our findings demonstrating a higher frequency of VTE 
in patients positive for PR3- ANCA. Moreover, patients with GPA 
exhibit an increased frequency of anticardiolipin antibodies when 
compared to the general population (14). The association between 
pulmonary hemorrhage and VTE in patients with AAV has not been 
previously described. A case series of patients with severe pulmo-
nary hemorrhage due to systemic vasculitis showed a concomitant 
VTE event in 7 of 35 patients (15). It is tempting to speculate that 
these patients are prone to develop thrombosis due to more severe 
 disease, as shown in our study. We found an association between 
the presence of urinary RBC casts and VTE, while renal involvement 
in general was not associated with VTE. One can speculate that 
presence of RBC casts is related to active glomerular inflammation 
and that inflammation in itself is triggering VTE.
Our work has several strengths and limitations. Since the 
RAVE study was a randomized controlled trial, the quality and 
completeness of the data (which are publicly accessible) are 
more appropriate compared to most other studies investi-
gating VTE. Among the study’s limitations, we only assessed 
clinically apparent VTE events (i.e., not investigated in a pro-
tocolized, prospective manner), and the definition of alveo-
lar hemorrhage was left to site investigators. Due to the low 
number of events, adjustment for multiple comparisons was 
restricted to age and sex. Moreover, data on some variables, 
such as serum albumin and proteinuria (measured by dipstick), 
were not available for every participant.
In conclusion, our post hoc analysis of a prospective rand-
omized controlled trial of patients with AAV has identified several 
factors associated with VTE risk. Patients with pulmonary hem-
orrhage may be prone to VTE. We identified PR3 positivity as a 
novel risk factor, which might be related to more frequent pres-
ence of antiplasminogen antibodies. The association between 
heart involvement and presence of RBCs has not been previously 
described and may reflect the contribution of overall disease bur-
den to the risk of thrombotic complications. Further studies are 
needed to confirm and expand these findings and to explore the 
mechanisms of hypercoagulability in these patients with the aim 
of informing potential targets for therapeutic interventions.
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